Sexy Design
True Power
Icon Paradise
Page Builder
Top Quality
Customizable
Hello. We’re Salient, A Creative Agency Located In New York City. Take A Look Around & Don’t Be Shy.
Phasellus enim libero, blandit vel sapien vitae, condimentum ultricies magna et. Quisque euismod orci ut et lobortis aliquam.
Phasellus enim libero, blandit vel sapien vitae, condimentum ultricies magna et. Quisque euismod orci ut et lobortis aliquam.
Phasellus enim libero, blandit vel sapien vitae, condimentum ultricies magna et. Quisque euismod orci ut et lobortis aliquam.
Phasellus enim libero, blandit vel sapien vitae, condimentum ultricies magna et. Quisque euismod orci ut et lobortis aliquam.
We Make Beautiful Things
35
Thousand
Theme Users
It takes a lot to be one of the most trusted themes on the market. Read more below why users keep coming back over and over again.
Unique Design
Take full control of the power Salient has to offer with our new exciting page builder. You’ll be grinning in delight when you see just how easy it is to create stunning layouts with little effort.
Page Builder
Take full control of the power Salient has to offer with our new exciting page builder. You’ll be grinning in delight when you see just how easy it is to create stunning layouts with little effort.
Continual Updates
Take full control of the power Salient has to offer with our new exciting page builder. You’ll be grinning in delight when you see just how easy it is to create stunning layouts with little effort.
Video Tutorials
Take full control of the power Salient has to offer with our new exciting page builder. You’ll be grinning in delight when you see just how easy it is to create stunning layouts with little effort.
Oh, & We Blog Sometimes
에이비온, 美 화생방학회 ‘CBD S&T’서 ABN101 발표…국내 최초 발표기업 선정
에이비온은 다음달 2일에서 5일까지 미국 플로리다주에서 열리는 화생방학회(Chemical and Biological Defense Science & Technology Conference)에…
Read More
에이비온, 바바메킵 2상 ‘레이저티닙 병용요법’ 코호트 추가…美 임상 변경 신청
에이비온은 MET 표적항암제 후보물질 '바바메킵(Vabametkib∙ABN401)'의 임상2상 시험계획 변경을 미국 식품의약국(FDA)에 신청했다고 11일 밝혔다. 시험 명칭은…
Read More
